Key terms
About INMD
InMode Ltd. designs, develops, manufactures and markets minimally-invasive aesthetic medical products. It also designs, develops, manufactures and markets non-invasive medical aesthetic products that target a array of procedures including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture and superficial benign vascular and pigmented lesions. The company was founded by Moshe Mizrahy and Michael Kreindel on January 2, 2008 and is headquartered in Yokneam, Israel.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest INMD news
Mar 15
10:14am ET
InMode’s (NASDAQ:INMD) Recent Slid Makes it a Potential Gem for Long-Term Value Investors
Mar 06
8:10am ET
Analysts Offer Insights on Healthcare Companies: Praxis Precision Medicines (PRAX), InMode (INMD) and Teladoc (TDOC)
Feb 21
3:35pm ET
SHAREHOLDER ALERT: Potential Recovery for InMode Ltd. (INMD) Investors
Feb 15
5:51am ET
InMode price target raised to $34 from $32 at Barclays
Feb 15
3:10am ET
Analysts Offer Insights on Healthcare Companies: IQVIA Holdings (IQV), Evolent Health (EVH) and InMode (INMD)
Feb 15
1:22am ET
InMode Receives Buy Rating from Baird Analyst Amidst Promising Outlook and Undervalued Stock
Feb 13
12:20pm ET
Analysts Conflicted on These Healthcare Names: Anixa Biosciences (ANIX) and InMode (INMD)
Jan 27
3:57pm ET
InMode Stock (NASDAQ:INMD): 2 Catalysts That Can Send Shares Skyrocketing
Jan 23
4:09am ET
Analysts Offer Insights on Healthcare Companies: MaxCyte (GB:MXCT), Kura Oncology (KURA) and InMode (INMD)
Jan 17
9:02am ET
InMode price target lowered to $32 from $33 at Barclays
Jan 16
5:02pm ET
InMode downgraded to Hold from Buy at Canaccord
Jan 16
3:49pm ET
InMode sees FY24 revenue $495M-$505M, consensus $524.18M
Jan 16
3:26pm ET
InMode sees FY23 EPS $2.54-$2.55, consensus $2.49
Jan 16
3:24pm ET
Correction: InMode sees FY23 EPS $2.54-$2.55, consensus $2.49
Jan 16
3:18pm ET
InMode sees Q4 EPS 68c-69c, consensus 63c
Jan 16
3:15pm ET
InMode sees FY23 EPS $2.54-$2.55, consensus $2.49
Jan 04
6:19am ET
InMode price target lowered to $33 from $45 at Barclays
No recent news articles are available for INMD
Yesterday
1:20pm ET
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of InMode
Mar 17
6:08pm ET
ROSEN, A GLOBALLY RECOGNIZED LAW FIRM, Encourages InMode Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action - INMD
Mar 15
9:10pm ET
ROSEN, A LONGSTANDING LAW FIRM, Encourages InMode Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action - INMD
Mar 15
10:18am ET
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of InMode
Mar 13
8:59am ET
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against InMode Ltd.- INMD
INMD Financials
Key terms
Ad Feedback
INMD Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
INMD Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range